1. Home
  2. DXLG vs MRKR Comparison

DXLG vs MRKR Comparison

Compare DXLG & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$0.72

Market Cap

34.5M

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.46

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXLG
MRKR
Founded
1976
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.5M
27.7M
IPO Year
1994
2010

Fundamental Metrics

Financial Performance
Metric
DXLG
MRKR
Price
$0.72
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.50
$10.00
AVG Volume (30 Days)
107.9K
69.6K
Earning Date
05-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
$435,017,000.00
N/A
Revenue This Year
$3.85
N/A
Revenue Next Year
$4.09
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.81
52 Week High
$1.69
$4.07

Technical Indicators

Market Signals
Indicator
DXLG
MRKR
Relative Strength Index (RSI) 59.10 47.32
Support Level $0.48 $1.34
Resistance Level $0.72 $1.52
Average True Range (ATR) 0.06 0.08
MACD 0.00 -0.01
Stochastic Oscillator 49.21 34.01

Price Performance

Historical Comparison
DXLG
MRKR

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

Share on Social Networks: